Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atgam for Japanese patients with aplastic anemia
NCT04350606Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of antithymocyte globulin in aplastic anemia, sponsored by Pfizer. Primary endpoint: Number of Participants With Hematologic Response at 12 weeks. Started Jul 2020; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT04350606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350606.